Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine

Executive Summary

/PRNewswire/ -- Oncoinvent, a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity...